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Abstract
Introduction: It was reported that proton beam therapy (PBT) reduced the normal brain dose compared with X-ray
therapy for pediatric brain tumors. We considered whether there was not the condition that PBT was more
disadvantageous than intensity modulated photon radiotherapy (IMRT) and 3D conventional radiotherapy (3D-CRT)
for treatment of pediatric brain tumors about the dose reduction for the normal brain when the tumor location or
tumor size were different.
Methods: The subjects were 12 patients treated with PBT at our institute, including 6 cases of ependymoma treated
by local irradiation and 6 cases of germinoma treated by irradiation of all four cerebral ventricles. IMRT and 3D-CRT
treatment plans were made for these 12 cases, with optimization using the same planning conditions as those for PBT.
Model cases were also compared using sphere targets with different diameters or locations in the brain, and the
normal brain doses with PBT, IMRT and 3D-CRT were compared using the same planning conditions.
Results: PBT significantly reduced the average dose to normal brain tissue compared to 3D-CRT and IMRT in all cases.
There was no difference between 3D-CRT and IMRT. The average normal brain doses for PBT, 3D-CRT, and
IMRT were 5.1–34.8% (median 14.9%), 11.0–48.5% (23.8%), and 11.5–53.1% (23.5%), respectively, in ependymoma cases;
and 42.3–61.2% (48.9%), 54.5–74.0% (62.8%), and 56.3–72.1% (61.2%), respectively, in germinoma cases. In the model
cases, PBT significantly reduced the average normal brain dose for larger tumors and for tumors located at the
periphery of the brain.
Conclusion: PBT reduces the average dose to normal brain tissue, compared with 3D-CRT and IMRT. The effect is higher
for a tumor that is larger or located laterally.
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Introduction
Deterioration of intelligence after radiotherapy is an
important problem in growing children. The degree of de-
terioration is affected by the irradiation dose, volume, site,
and age at irradiation [1]. A major concern of brain irradi-
ation in pediatric patients is subsequent deterioration of
intelligence [6–10], since neurodevelopment is affected by
the treatment dose and age at irradiation [1, 11, 12]. In 4
patients among 27 children with medulloblastoma treated
with craniospinal irradiation with a posterior fossa boost,
Walter et al. [8] found an IQ decline of 3.9 points per year
during a median observation period of 4.8 years, and cog-
nitive losses did not seem to have reached a plateau.
Merchant et al. analysed the correlation with the degree of
deterioration and DVH of the whole brain and suggested
that IQ can be obtained from the following formula [1]:
IQ ¼ 93:11  ð0:028  age ‐ 0:0095
 average dose to the brainÞ  time
Intensity modulated photon radiotherapy (IMRT) is
now widely used and can reduce the dose to an at-risk
organ and decrease the high dose area, but the low dose
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area is wider than 3D-CRT. [13] X. Sharon et al. found that
IMRT redused temporal lobe dose compared with 3D-CRT
[14], but it is possible that the dose reduction for temporal
lobe by IMRT increase the dose of the other lobes, and
don’t reduce average dose to the brain compare with 3D-
CRT. In contrast, proton beam therapy (PBT) has a sharp
energy peak, referred to as the Bragg peak, which produces
excellent dose localization and reduces the dose to normal
tissue [2, 15, 16]. Therefore, excellent tumor coverage can
be achieved with a small number of beam ports, and several
reports have shown advantages of PBTcompared to photon
radiotherapy, including IMRT. [3] The advantages of PBT
compared to photon radiotherapy including IMRT have
been described in treatment of pediatric CNS tumors
[9–11]. MacDonald et al. found that proton beams
can achieve tumor coverage as well as IMRT, but that
normal tissue sparing was better in PBT for patients
with germ cell tumor and ependymoma [17, 18].
We conduct PBT for all pediatric patients with brain
malignancies who are indicated for photon radiotherapy in
order to reduce the normal brain dose [4, 5]. However, the
conditions under which the advantages of PBT are maxi-
mized are unclear; for example, a large or small tumor, local
or whole-ventricle irradiation, and a peripheral or central
tumor. In this study, we evaluated the more advantageous
condition of PBT for pediatric brain tumors in comparison
to 3D-CRT and IMRT, using quantitative analysis of
localized irradiation for ependymoma cases and whole-
ventricular irradiation for germinoma cases, and model
cases that targets were different size or location.
Patients and methods
Patients
The subjects were 12 pediatric patients (Table 1) with
brain tumors treated with PBT at our institute from
2009 to 2011. The study was approved by the institutional
review board at our institution. Six patients (3 males, 3
females; median age 4 [range: 2–6] years old) had ependy-
moma and 6 had germinoma (3 males, 3 females; median
age 13 [range: 10–16] years old). Localized and
whole-ventricle irradiation was performed for ependy-
moma and germinoma, respectively, during which the
patients were immobilized using individually manufac-
tured thermoplastic masks.
Comparison of PBT, IMRT, and 3D-CRT
Proton beams from 155 to 250 MeV, generated through
a linear accelerator and synchrotron, were spread out
and shaped with ridge filters, double-scattering sheets,
multicollimators, and custom-made boluses to ensure
that the beams conformed to the treatment planning
data. Planning CT images were taken at 2-mm intervals.
IMRT and 3D-CRT treatment plans were generated and
optimized using the same practical treatment planning
CT as that used for PBT to compare dose distributions
among the three methods. The prescribed doses were
the same in each cases among the three methods, 45Gy
to 61.2Gy (median 52.2Gy) in ependymoma cases as
local irradiation, and 24Gy to 30.6Gy (median 30.6Gy) in
germinoma cases as whole ventricle irradiation. All PBT
plans were prescribed the same dose with IMRT/3DCRT
as the equivalent dose. The clinical target volume (CTV)
for ependymoma was defined as the surgical defect plus
a margin of 0.5 to 1 cm. The CTV for germinoma was
defined as all cerebral ventricles. The same planning
target volume (PTV) and at-risk organ was re-contoured
for the photon radiotherapy plans. The PTV was identi-
cal for PBT, IMRT, and 3D-CRT for each patient and
was defined by the 95% iso-dose line in all plans. The
maximal dose prescriptions for at-risk organs were
<4 Gy for the lens and <50 Gy for the brainstem and
chiasma. We used helical tomotherapy that delivered 51
Table 1 Clinical background of patients










1 6 M Ependymoma 6.9 11.0 11.5 5.1 53.6 55.7
2 6 M Ependymoma 74.0 20.5 20.1 14.4 29.8 28.4
3 2 F Ependymoma 6.1 17.8 17.1 6.5 63.5 62.0
4 3 F Ependymoma 42.5 30.0 31.8 15.4 48.7 51.6
5 4 M Ependymoma 116.3 48.5 53.1 34.8 28.2 34.5
6 3 F Ependymoma 48.0 27.0 26.9 16.7 38.1 37.9
7 11 M Germinoma 344.8 74.0 72.1 61.2 17.3 15.1
8 16 F Germinoma 150.2 60.5 61.8 48.5 19.8 21.5
9 10 M Germinoma 168.8 54.5 56.3 42.3 22.4 24.9
10 14 M Germinoma 200.6 63.0 62.7 49.2 21.9 21.5
11 14 F Germinoma 216.7 67.0 60.6 55.0 17.9 9.2
12 12 F Germinoma 353.8 62.5 58.9 47.4 24.2 19.5
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of discrete gantry positions per rotation for IMRT plan-
ning, and two or more gantry angles that made the mini-
mum average normal brain dose and didn’t pass the eyes
for 3D-CRT and PBT planning. SOBP for PBT plans
were prescribed by a 1 cm unit and chosed the smallest
width as far as PTV covers were enough in the condi-
tion. Leaf margin of the PBT plans and 3D-CRT plans
also optimized the smallest width as far as PTV covers
were enough in the condition. All planning optimization
were checked two radiotherapists. Statistical analysis was
performed using t-test in SPSS (SPSS Inc., Chicago, IL,
USA). Dose-volume histograms (DVHs) for the normal
brain were calculated for PBT, IMRT, and 3D-CRT and
compared among the methods.
Model cases
To assess the advantages of PBT based on tumor size
and location, model target spheres of different sizes and
locations were evaluated. Targets were first prepared
with the iso-center at the center of the brain and diame-
ters of 2, 3, 4, and 6 cm to analyze the effect of target
size. Secondly, a target of 4 cm in diameter was moved
from the center of the brain to the peripheral region
horizontally in a right-left direction (x-axis) at 1-cm
intervals to analyze the effect of target location. Dose
distributions for each target were calculated for PBT,
3D-CRT, and IMRT, and the normal brain dose was
evaluated as a percentage of the prescription dose. The
relative decrease in normal brain dose in PBT compared
to 3DCRT or IMRT was calculated from the equation:
The relative decrease in brain average dose
¼ IMRT or 3D − CRT brain average dose − PBT brain average dose
IMRT or 3D−CRT brain average dose
Results
Ependymoma cases (local irradiation)
Doses to normal brain tissue in PBT, 3D-CRT, and
IMRT for the 6 patients with ependymoma are shown in
Fig. 1. In the respective methods, the average normal
brain doses were 15.5, 25.8, and 26.8% of the prescrip-
tion dose. Normal brain doses were significantly lower
in PBT compared to 3D-CRT (p = 0.001) and IMRT (p =
0.003), with differences ranging from 5.7 to 18.3%
(median 10.5%). The relative decreases were 28.2 to
63.4% (median 43.4%) compared to 3D-CRT and 28.4 to
62.0% (median 44.7%) compared to IMRT. There was no
significant difference in the normal brain dose between
IMRT and 3D-CRT (p = 0.296).
Germinoma cases (whole-ventricle irradiation)
Doses to normal brain tissue in PBT, 3D-CRT, and
IMRT for the 6 patients with germinoma are shown in
Fig. 2. The average normal brain doses were 50.6, 63.6,
and 62.1% of the prescription dose, respectively. Normal
brain doses were significantly smaller in PBT compared
to 3D-CRT and IMRT (both p = 0.000), with differences
ranging from 5.6 to 15.1% (median 12.5%). The relative
decreases were 17.3 to 24.1% (median 20.9%) compared
to 3D-CRT and 9.2 to 24.9% (median 20.5%) compared
to IMRT. There was no significant difference in the
normal brain dose between IMRTand 3D-CRT (p = 0.287).
Figure 3 shows the example of the treatment planning
of ependymoma and germinoma in each methods.
Model cases
The normal brain doses for targets of diameters 2, 3, 4,
and 6 cm with the iso-center at the brain center were
5.5, 8.5, 14.5, and 28% of the prescription dose in PBT;
11.5, 17.5, 25.5, and 41.5% in 3D-CRT; and 13.4, 18.5,
24.9, and 39.8% in IMRT, respectively (Fig. 4). For all
targets, the average normal brain dose was smaller in
PBT plans compared to 3D-CRT (p = 0.008) and IMRT
(p = 0.001), with no significant difference between
3D-CRT and IMRT (p = 0.886). There were significant
Fig. 1 Average normal brain doses for patients with ependymoma
Fig. 2 Average normal brain doses for patients with germinoma
Takizawa et al. Radiation Oncology  (2017) 12:40 Page 3 of 7
positive correlations between target size and normal
brain dose (p = 0.000 for PBT, p = 0.002 for 3D-CRT,
p = 0.003 for IMRT); if the target was larger, the aver-
age normal brain dose was larger in all three
methods. There were also significant positive correla-
tions between target size and the difference in normal
brain dose in PBT compared to 3D-CRT (p = 0.023)
and IMRT (p = 0.048); if the target was larger, there
was a larger reduction in normal brain dose in PBT
compared to radiotherapy.
Regarding target location, and with use of bilateral
irradiation for 3D-CRT and PBT, the average normal
brain doses for targets with iso-centers at 0, 1, 2, 3, and
4 cm from the brain center were 14.5%, 14.0%, 14.0%,
14.0%, 14.0% of the prescription dose for PBT; 25.5,
25.0, 25.0, 25.0, and 24.0% for 3D-CRT; and 24.9, 24.5,
23.9, 23.0% and 22.1% for IMRT, respectively (Fig. 5).
For all target locations, the normal brain doses were sig-
nificantly smaller in PBT plans compared to 3D-CRT
and IMRT (both p = 0.000), and in IMRT plans
Fig. 3 The example of the treatment planning of ependymoma and germinoma in each methods
Fig. 4 a Average normal brain dose for each treatment plan with sphere targets with the same iso-center as the brain center and different diameters
(2, 3, 4, 6 cm). b Correlation between target size and difference in normal brain dose in PBT compared to 3DCRT or IMRT
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compared to 3D-CRT (p = 0.018). There was no correl-
ation between target location and normal brain dose in
PBT (p = 0.182). In 3D-CRT, the normal brain dose
tended to decrease when the target was more peripheral,
but the difference was not significant (p = 0.058). In
IMRT, the normal brain dose was significantly decreased
when the target moved peripherally (p = 0.016). The
difference in normal brain dose between PBT and
3D-CRT was not significantly correlated with target
location (p = 0.182), but that between PBT and IMRT was
significantly correlated with target location (p = 0.014).
Using two oblique angle irradiation for 3D-CRT and
PBT, the average normal brain doses for targets with
iso-centers 0, 1, 2, 3, and 4 cm from the brain center
were 14.5%, 14.0%, 12.3%, 10.2%, 8.4% of the prescrip-
tion dose for PBT; and 25.5, 25, 23.5, 22, and 21.5%
for 3D-CRT, respectively (Fig. 6). IMRT gave the same
results as those given above. For all target locations,
the normal brain dose was significantly smaller in
PBT plans compared to 3D-CRT and IMRT (both p =
0.000). There was no difference between IMRT and
3D-CRT (p = 0.649). There were significant positive
correlations between target position and difference in
normal brain dose in PBT compared to 3DCRT (p =
0.006) and IMRT (p = 0.004); if the target was more per-
ipheral, there was a larger reduction in normal brain dose
in PBT compared to radiotherapy.
Discussion
Proton beam therapy reduces the low dose area for
pediatric brain tumor, and it gradually becomes the
common recognition [19]. Radiation induce emotional
and behavioral deficits and those are remain long time
[20]. There were reports indicate that the average dose
to the brain is an important factor for future IQ [1]. In
this study, we focused on the average dose to normal
brain tissue, and we found that PBT can substantially
reduce this dose, compared to IMRT and 3D-CRT. This
result matches past reports [21, 22]. Table 2 shows the
difference in the expected IQ after 10 years by using
PBT instead of X-ray therapy. PBT was expected de-
creasing the degree of the 3.4 to 12.8 IQ point in
Fig. 5 Average normal brain dose for each treatment plan, using
bilateral irradiation for 3D-CRT and PBT, with sphere targets with the
same diameter and different iso-centers at 0, 1, 2, 3, and 4 cm from
the brain center
Fig. 6 a Average normal brain dose for each treatment plan, using two oblique angle irradiation for 3D-CRT and PBT, with sphere targets with
the same diameter and different iso-centers at 0, 1, 2, 3, and 4 cm from the brain center. b Correlation between target position and difference in
normal brain dose in PBT compared to 3DCRT or IMRT
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ependymoma cases, and 1.3 to 5.3 point IQ point in
germinoma cases. This advantage was found in local ir-
radiation for ependymoma and whole-ventricle irradi-
ation for germinoma, with reductions of almost 40 and
20%, respectively. This effect may produce a 5-point dif-
ference in IQ at entrance to senior high school for a pa-
tient with ependymoma who received radiotherapy at
4 years old, and a 3-point difference at high-school gradu-
ation for a patient with germinoma who received radio-
therapy at age 13.
The advantages of PBT compared to photon radiother-
apy including IMRT have been described in treatment of
pediatric CNS tumors [9–11]. MacDonald et al. found that
proton beams can achieve tumor coverage as well as
IMRT, but that normal tissue sparing was better in PBT
for patients with germ cell tumor and ependymoma
[17, 18]. Our results are similar to these reports [5, 23].
In addition, PBT is more effective than IMRT or 3D-CRT
for treatment of a large or peripheral tumor. For tumor
location, the reduction in the dose to normal brain tissue
was large when the target was outside over 2 cm from the
brain center. Regarding the model case of the differential
target position, we used sphere targets of diameters 4 cm,
and this distance was equal to the target radius, which
suggests that an advantage of PBT may emerge when the
target does not cross the midline of the brain.
From the result of treated case and model case, we found
no case that PBT has disadvantage compared with X-ray
therapy about normal brain dose, but if the tumor was cen-
ter and small, the benefit of using PBT was small relatively.
Recently it was reported that age and mean radiation dose
to specific brain volumes, including the temporal lobes and
hippocampi, had a significant impact on longitudinal scores
[24]. It is future problem to analyze the risk organ in vain,
and it is necessary that assessing not only about brain tu-
mors, but also about body tumors.
Conclusion
PBT has maximum advantage about normal brain dose
for a larger and peripheral tumor, and there was no case
that PBT has disadvantage. The dose to normal brain
tissue is lower with PBT compared with 3D-CRT and
IMRT in local and whole-ventricle irradiation. This
information matches past reports.
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1. 6 M Ependymoma 50.4 2.97 3.23 3.4 3.7
2. 6 M Ependymoma 54.0 3.29 3.08 3.8 3.5
3. 2 F Ependymoma 50.4 5.70 5.34 6.5 6.1
4. 3 F Ependymoma 59.4 8.67 9.74 9.9 11.1
5. 4 M Ependymoma 61.2 8.38 11.20 9.6 12.8
6. 3 F Ependymoma 45.0 4.64 4.59 5.3 5.2
7. 11 M Germinoma 30.6 3.92 3.34 4.5 3.8
8. 16 F Germinoma 30.6 3.67 4.07 4.2 4.6
9. 10 M Germinoma 30.6 3.73 4.28 4.3 4.9
10. 14 M Germinoma 30.6 3.92 3.83 4.5 4.4
11. 14 F Germinoma 24.0 2.88 1.34 3.3 1.5
12. 12 F Germinoma 30.6 4.62 3.52 5.3 4.0
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